Stock Ratings / Health Care / JNJ / insiders

ABBV (81) MRK (75) NVS (66) AZN (62) ⌘ Pro Terminal →

Johnson & Johnson (JNJ) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$275.20 +1.54% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)

Johnson & Johnson (JNJ) earns a Roarable Rating of A- (Buy) with 82/100 RQD Confidence. High-quality cash engine (68% profit margin, 26% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A- • BUY Cap $662.49B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • A-

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk A-

Each axis scored 0–20

12M PRICE TARGET CONE+10.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for JNJ)Realized 20D OHLCV Swing Band: ±5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

JNJ Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (JNJ)

No recent open-market Form 4 cluster sales or emergency dumps flagged on JNJ. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (JNJ Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 1,540+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

JNJ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.75%📐 HORIZONTAL RANGE

2026-11-01O $271.0H $275.2L $271.0C $275.2VOL 6.02M

RES: $291.0SUP: $243.7SMA50: $265.7SMA200: $247.3

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

JNJ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 JNJ Butterfly Map → + Track JNJ →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.4%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on JNJ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for JNJ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for JNJ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (JNJ)

Health Care Rank #7 of 188 ⚔️ ABBV vs JNJ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (JNJ vs. ABBV, MRK, NVS, AZN)

Industry: Biotechnology: Pharmaceutical Preparations (64 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, Johnson & Johnson (JNJ) ranks #7 by composite RQD confidence (82/100, grade A-) and #2 by equity capitalization ($662.49B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while ABBV leads on capital efficiency and profitability with 29.0% ROIC and 70.2% gross margin. JNJ currently leads its immediate peer cohort in composite quantitative strength at 82/100 (A-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
JNJ ACTIVE Johnson & Johnson	A-	82/100	24.7x	67.9%	25.5%	+1.54%	$662.49B	Benchmark Subject
ABBV AbbVie Inc.	A-	81/100	121.6x	70.2%	29.0%	+1.68%	$513.86B	/abbv-vs-jnj →
MRK Merck & Company Inc.	B	75/100	19.8x	74.8%	20.7%	+3.83%	$361.02B	/mrk-vs-jnj →
NVS Novartis AG	C+	66/100	32.8x	—	9.9%	+3.22%	$307.40B	/nvs-vs-jnj →
AZN AstraZeneca PLC	C	62/100	32.8x	—	9.9%	+2.89%	$270.45B	/azn-vs-jnj →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0000200406

In its most recent audited fiscal period (FY2025, filed 2025-12-28), Johnson & Johnson (JNJ) reported GAAP revenue of $94.19B (+6.0% vs. FY2024 revenue of $88.82B , and +10.6% cumulative change since FY2023) , GAAP net income of $26.80B, operating cash flow of $24.53B, and free cash flow of $19.70B (-0.7% YoY). On the balance sheet, JNJ closed FY2025 with $199.21B in total assets against $39.44B in total debt (Altman Z-Score: 5.59, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-28	$94.19B	$26.80B	$24.53B	$19.70B	$199.21B	$39.44B
FY2024 (FY)	2024-12-29	$88.82B	$14.07B	$24.27B	$19.84B	$180.10B	$30.65B
FY2023 (FY)	2023-12-31	$85.16B	$35.15B	$22.79B	$18.96B	$364.37B	$85.26B

3. JNJ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is JNJ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Johnson & Johnson (NYSE: JNJ) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 82/100 at a spot price of $275.20 (+1.54% 1D, market cap $662.49B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 188 tracked Health Care issuers, JNJ ranks #7 in composite RQD confidence.

How does JNJ compare to ABBV and MRK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), JNJ carries a Roarable A- (82/100 RQD), trailing P/E of 24.7x, gross margin of 67.9%, and ROIC of 25.5%. By comparison, ABBV (AbbVie Inc.) holds a A- grade (81/100 RQD, P/E 121.6x, ROIC 29.0%, cap $513.86B) and MRK (Merck & Company Inc.) posts a B grade (75/100 RQD, P/E 19.8x, ROIC 20.7%, cap $361.02B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while ABBV leads on capital efficiency (29.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for JNJ?

Per JNJ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000200406), Johnson & Johnson generated $94.19B in revenue (+6.0% YoY), $26.80B in net income, and $19.70B in free cash flow against $199.21B in total assets and $39.44B in total debt. Key quantitative strengths: Strong cash generator (68% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is JNJ trading relative to its 50-day, 200-day, and 52-week technical levels?

JNJ last traded at $275.20 (+1.54% on volume of 6,023,633 shares), positioning the stock +3.58% above its 50-day simple moving average ($265.70) and +11.30% above its 200-day simple moving average ($247.26). Across its 52-week range of $185.12 to $282.02, JNJ sits at the 93.0% percentile with a 14-day RSI of 62.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($261.44 to $288.96).

JNJ Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are JNJ insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies JNJ leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: JNJ RQD Cockpit JNJ 12M Forecast JNJ Earnings & Move JNJ Dividends & DRIP JNJ Insiders & 13F JNJ Whale Options JNJ Profit Sankey JNJ News & Why